Journal ArticleDOI
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Inessa Schwab,Falk Nimmerjahn +1 more
TLDR
The recent insights into the molecular and cellular pathways that are involved in IVIG-mediated immunosuppression are covered, with a particular focus on IVIG as a therapy for IgG-dependent autoimmune diseases.Abstract:
Intravenous immunoglobulin (IVIG) preparations comprise pooled IgG antibodies from the serum of thousands of donors and were initially used as an IgG replacement therapy in immunocompromised patients. Since the discovery, more than 30 years ago, that IVIG therapy can ameliorate immune thrombocytopenia, the use of IVIG preparations has been extended to a wide range of autoimmune and inflammatory diseases. Despite the broad efficacy of IVIG therapy, its modes of action remain unclear. In this Review, we cover the recent insights into the molecular and cellular pathways that are involved in IVIG-mediated immunosuppression, with a particular focus on IVIG as a therapy for IgG-dependent autoimmune diseases.read more
Citations
More filters
Journal ArticleDOI
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
TL;DR: It is shown that SARS-Cov-2 selectively induces a high level of IL-6 and results in the exhaustion of lymphocytes, and the current evidence indicates that tocilizumab, an IL- 6 inhibitor, is relatively effective and safe.
Journal ArticleDOI
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals,Julie R. Brahmer,Margaret K. Callahan,Margaret K. Callahan,Alejandra Flores-Chávez,Niamh M. Keegan,Munther A. Khamashta,Olivier Lambotte,Xavier Mariette,Aleix Prat,Maria E. Suarez-Almazor +10 more
TL;DR: This Primer by Ramos-Casals and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of immune-related adverse events and should be prescribed carefully to reduce the potential of short-term and long-term complications.
Journal ArticleDOI
The function of Fcγ receptors in dendritic cells and macrophages
TL;DR: How the uptake, processing and presentation of antigens by DCs and macrophages is influenced by FcγR recognition of immunoglobulins and immune complexes in the steady state and during inflammation is discussed.
Journal ArticleDOI
Management of Immunotherapy-Related Toxicities, Version 1.2019.
John A. Thompson,Bryan J. Schneider,Julie R. Brahmer,Stephanie Andrews,Philippe Armand,Shailender Bhatia,Lihua E. Budde,Luciano J. Costa,Marianne Davies,David Dunnington,Marc S. Ernstoff,Matthew J. Frigault,Brianna Hoffner,Christopher J. Hoimes,Mario E. Lacouture,Frederick L. Locke,Matthew A. Lunning,Nisha Mohindra,Jarushka Naidoo,Anthony J. Olszanski,Olalekan O. Oluwole,Sandip Pravin Patel,Sunil Reddy,Mabel Ryder,Bianca Santomasso,Scott Shofer,Jeffrey A. Sosman,Momen M. Wahidi,Yinghong Wang,Alyse Johnson-Chilla,Jillian L. Scavone +30 more
TL;DR: The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence.
Journal ArticleDOI
Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke
Yang-Wei Fann,S-Y Lee,Silvia Manzanero,Sung-Chun Tang,Mathias Gelderblom,Prasad Chunduri,Christian Bernreuther,Markus Glatzel,Yi-Lin Cheng,John Thundyil,Alexander Widiapradja,Ker Zhing Lok,S L Foo,Y-C Wang Wang,Y-I Li,Grant R Drummond,Milan Basta,Tim Magnus,Dong-Gyu Jo,Mark P. Mattson,Christopher G. Sobey,Thiruma V. Arumugam,Thiruma V. Arumugam,Thiruma V. Arumugam +23 more
TL;DR: Evidence is provided that the NLRP1 and NLRP3 inflammasomes have a major role in neuronal cell death and behavioral deficits in stroke, and that IVIg treatment can protect brain cells against ischemic damage, suggesting a potential clinical benefit of therapeutic interventions that targetinflammasome assembly and activity.
References
More filters
Journal ArticleDOI
Fcγ receptors as regulators of immune responses
TL;DR: Recent studies addressing the multifaceted roles of FcRs for IgG (FcγRs) in the immune system are discussed and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases are discussed.
Journal ArticleDOI
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
Jane W. Newburger,Masato Takahashi,Michael A. Gerber,Michael H. Gewitz,Lloyd Y. Tani,Jane C. Burns,Stanford T. Shulman,Ann F. Bolger,Patricia Ferrieri,Robert S. Baltimore,Walter R. Wilson,Larry M. Baddour,Matthew E. Levison,Thomas J. Pallasch,Donald A. Falace,Kathryn A. Taubert +15 more
TL;DR: Recommendations for the initial evaluation, treatment in the acute phase, and long-term management of patients with Kawasaki disease are intended to assist physicians in understanding the range of acceptable approaches for caring for patients withawasaki disease.
Journal ArticleDOI
High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR
Robert L. Shields,Angela K. Namenuk,Kyu Hong,Y. Gloria Meng,Julie Rae,Josephine P. Briggs,Dong Xie,Jadine Lai,Andrew Stadlen,Betty Li,Judith A. Fox,Leonard G. Presta +11 more
TL;DR: Select IgG1 variants with improved binding to FcγRIIIA exhibited up to 100% enhancement in antibody-dependent cell cytotoxicity using human effector cells; these variants included changes at residues not found at the binding interface in the IgG/Fcγ RIIIA co-crystal structure.
Journal ArticleDOI
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
TL;DR: It is shown that IgG acquires anti-inflammatory properties upon Fc sialylation, which is reduced upon the induction of an antigen-specific immune response, and may provide a switch from innate anti- inflammatory activity in the steady state to generating adaptive pro-inflammatory effects upon antigenic challenge.
Journal ArticleDOI
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
Paul Imbach,V. d'APUZZO,Andreas Hirt,E. Rossi,M. Vest,Silvio Barandun,C. Baumgartner,Andreas Morell,Martin H. Schöni,H. P. Wagner +9 more
TL;DR: Seven children with chronic or intermittent ITP and six with acute idiopathic thrombocytopenic purpura were treated with large intravenous doses of polyvalent, intact immunoglobulin (Ig), and the platelet count rose sharply within 5 days, but the initial response and the subsequent course varied from patient to patient.